Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754740 | 1.00 | GLO1 (0.46) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL5753353 | 1.00 | GLO1 (0.46) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL11547520 | 0.87 | GLO1 (0.57) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL16285258 | 0.84 | HPGD (0.46) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL5750889 | 0.84 | ALDH1A1 (0.38) | GLO1KDM4EALDH1A1POLBGAA | |
| SCHEMBL5750890 | 0.84 | ALDH1A1 (0.38) | GLO1KDM4EALDH1A1POLBGAA | |
| SCHEMBL5755286 | 0.84 | ALDH1A1 (0.38) | GLO1KDM4EALDH1A1POLBGAA | |
| SCHEMBL9476279 | 0.83 | AKR1C3 (0.51) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL9476285 | 0.83 | AKR1C3 (0.51) | GLO1CYP1A2CYP2C9FBP1KMT2A | |
| SCHEMBL5751671 | 0.82 | PTGS1 (0.47) | GLO1CYP1A2FBP1AKR1C3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | GLO1 1086/4885CYP1A2 52/4885CYP2C9 59/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | GLO1 1086/4885CYP1A2 52/4885CYP2C9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.